A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Conditions
Plasmablastic Lymphoma · Ann Arbor Stage I Diffuse Large B-Cell Lymphoma · Ann Arbor Stage II Diffuse Large B-Cell Lymphoma · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma · Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami Miller School of Medicine, Miami, Florida, United States
Contact: Principal Investigator (Juan C Ramos, MD)University of Illinois at Chicago, Chicago, Illinois, United States
Contact: Principal Investigator (Paul Rubinstein, MD)Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Contact: Principal Investigator (Richard Ambinder, MD)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Ariela Noy, MD)University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Christopher Dittus, DO, MPH)The Ohio State University, Columbus, Ohio, United States
Contact: Principal Investigator (Robert Baiocchi, MD, PhD)University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Tanya Latorre, BSN, RN, OCN) · Tanya.Latorre@pennmedicine.upenn.edu · 215-629-6874Contact: Principal Investigator (Stefan Barta, MD)The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Raphael Steiner, MD) · cr_study_registration@mdanderson.org · 713-792-7734Contact: Principal Investigator (Raphael Steiner, MD)
Study leads
Ariela Noy, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center